The company missed analyst estimates on its top line, but beat analyst estimates for adjusted earnings per share and raised its adjusted EPS guidance for FY 2017.
The company's new FACSLyric flow cytometer system is for use with BD Multitest assays for assessing suspected immunological deficiencies in patients.
Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.
The firm said that the test, which detects infectious diarrhea caused by harmful intestinal bacteria, extends the BD MAX Enteric Panel Portfolio.
The offering of $2.25 billion of common stock was priced at $176.50 per share, while the offering of $2.25 billion in depositary shares was priced at $50 per share.
Proceeds from the offerings will be used to finance a portion of the cash consideration in connection with BD's $24 billion acquisition of C.R. Bard.
The deal gives BD global distribution rights for several Bruker MALDI Biotyper products, expanding a 2010 agreement key to both firms' microbiology businesses.
BD Life Sciences revenues rose 5 percent to $982 million, driven by strong growth in diagnostics products, which were up 10 percent.
The firms expect that the acquisition will yield a medical technology company positioned to improve the process of care and the treatment of disease.